Zatolmilast - Tetra Therapeutics
Alternative Names: BPN-14770Latest Information Update: 12 Dec 2024
Price :
$50 *
At a glance
- Originator Tetra Discovery Partners
- Developer Tetra Therapeutics
- Class Acetamides; Amines; Antidementias; Benzeneacetamides; Chlorobenzenes; Fluorinated hydrocarbons; Pyrimidines; Small molecules
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Alzheimer's disease; Cognition disorders
Highest Development Phases
- Phase II/III Fragile X syndrome
- Phase II Alzheimer's disease
Most Recent Events
- 12 Dec 2024 Shionogi plans a phase II trial for Neurodevelopmental disorders (In children, In adolescents, In adults) in USA (PO), in January 2025 (NCT06717438)
- 18 Jul 2024 Zatolmilast receives Fast Track designation for Fragile X syndrome [PO,Capsule] (In adults) in USA before July 2024
- 11 Apr 2024 Zatolmilast - Tetra Therapeutics receives Orphan Drug status for Fragile X syndrome in European Union